CoChat
Sign Up
Cited by 44

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Changes in Matrix Proteoglycans Induced by Insulin and Fatty Acids in Hepatic Cells May Contribute to Dyslipidemia of Insulin Resistance

Olsson, Urban, Egnell, Ann-Charlotte, Lee, Mariam Rodríguez, Lundén, Gunnel Östergren, Lorentzon, Malin, Salmivirta, Markku, Bondjers, Göran, Camejo, Germán·2001·Diabetes
DOI 10.2337/diabetes.50.9.2126
Open this paper in CoChat — free account

Abstract

Insulin resistance and type 2 diabetes are associated with elevated circulating levels of insulin, nonesterified fatty acids (NEFAs), and lipoprotein remnants. Extracellular matrix proteoglycan (PG) alterations are also common in macro- and microvascular complications of type 2 diabetes. In liver, extracellular heparan sulfate (HS) PGs contribute to the uptake of triglyceride-rich lipoprotein remnants. We found that HepG2 cells cultured with 10 or 50 nmol/l insulin or 300 μmol/l albumin-bound linoleic acid changed their PG secretion. The glycosaminoglycans (GAGs) of the secreted PGs from insulin-treated HepG2 cells were enriched in chondroitin sulfate (CS) PGs. In contrast, cells exposed to linoleic acid secreted PGs with decreased content of CS. Insulin caused a moderate increase in mRNA for versican (secreted CS PG), whereas linoleic acid markedly decreased mRNA for versican in HepG2 cells, as did the peroxisomal proliferator-activated receptor-α agonist bezafibrate. The effects of insulin or linoleic acid on syndecan 1, a cell surface HS PG, were similar to those on versican, but less pronounced. The livers of obese Zucker fa/fa rats, which are insulin-resistant and have high levels of insulin, NEFAs, and triglyceride-rich remnants, showed increased expression of CS PGs when compared with lean littermates. These changes in PG composition decreased the affinity of remnant β-VLDL particles to PGs isolated from insulin-treated HepG2 cells and obese rat livers. The results indicated that insulin and NEFAs modulate the expression of PGs in hepatic cells. We speculate that in vivo this exchange of CS for HS may reduce the clearance of remnant β-VLDLs and contribute to the dyslipidemia of insulin resistance.

Overview

Integrity signals

Registry

Crossref · 10.2337/diabetes.50.9.2126

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 1 references

Research works printed but not linked: 30

  1. Lehto S, Rönnema T, Haffner S, Pyörälä K, Kallio V, Laakso M: Dyslipidemia and hyperglycemia predict coronary heart disease events in middle-aged patients with NIDDM. Diabetes 46:1354–1359, 1997 · DOI
  2. Camejo G: The interaction of lipids and lipoproteins with the intercellular matrix of arterial tissue: its possible role in atherogenesis. Adv Lipid Res 19:1–54, 1982 · DOI
  3. Camejo G, Hurt-Camejo E, Wiklund O, Bondjers G: Association of lipoproteins with arterial proteoglycans: pathological significance. Atherosclerosis 139:205–222, 1998 · DOI
  4. Williams K, Tabas I: The response-to-retention hypothesis of atherogenesis reinforced. Curr Opin Lipidol 9:471–474, 1998 · DOI · Paper page
  5. Ji Z, Brecht WJ, Miranda RD, Hussain MM, Innerarity TL, Mahley RW: Role of heparan sulfate proteoglycans in the binding and uptake of apolipoprotein E-enriched remnant lipoproteins by cultured cells. J Biol Chem 268:10160–10167, 1993 · DOI · Paper page
  6. Mahley RW, Ji Z: Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res 40:1–16, 1999 · DOI · Paper page
  7. Olsson U, Bondjers G, Camejo G: Fatty acids modulate the composition of extracellular matrix in cultured human arterial smooth muscle cells by altering the expression of genes for proteoglycan core proteins. Diabetes 48:616–622, 1999 · DOI
  8. Hennig B, Lipke DW, Biossonneault GA, Ramasamy S: Role of fatty acids and eicosanoids in modulating proteoglycan metabolism in endothelial cells. Prostaglandins Leukot Essent Fatty Acids 53:315–324, 1995 · DOI
  9. Hurt-Camejo E, Camejo G, Rosengren B, Lopez F, Wiklund O, Bondjers G: Differential uptake of proteoglycan-selected subfractions of low density lipoprotein by human macrophages. J Lipid Res 31:1387–1398, 1990 · DOI
  10. Ramasamy S, Boissenault GA, Lipke DW, Hennig B: Proteoglycans and endothelial barrier function: effect of linoleic acid exposure to porcine pulmonary artery endothelial cells. Atherosclerosis 103:279–290, 1993 · DOI
  11. Sartipy P, Johansen B, Camejo G, Rosengren B, Bondjers G, Hurt-Camejo E: Binding of human phospholipase A2 type II to proteoglycans: differential effect of glycosaminoglycans on enzyme activity. J Biol Chem 271:26307–26314, 1996 · DOI
  12. Fager G, Camejo G, Olsson U, Östergren-Lunden G, Lustig F, Bodjers G: Binding of platelet derived growth factor and low density lipoproteins to glycosaminoglycan species produced by human smooth muscle cells. J Cell Physiol 163:380–392, 1995 · DOI
  13. Alves CS, Murao PAS: Interaction of high molecular weight chondroitin sulfate from human aorta with plasma low density lipoprotein. Atherosclerosis 73:113–124, 1988 · DOI
  14. Safaiyan F, Lindahl U, Salmivirta M: Selective reduction of 6-O-sulfation in heparan sulfate from transformed mammary epithelial cells. Eur J Biochem 252:576–582, 1998 · DOI
  15. Lemire JM, Braun KR, Maurel P, Kaplan ED, Schwartz SM, Wight TN: Versican/PG-M isoforms in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 19:1630–1639, 1999 · DOI
  16. Hurt-Camejo E, Camejo G, Sartipy P: Measurements of proteoglycan-lipoprotein interaction by gel mobility shift assay. In Methods in Molecular Biology. Ordovas JM, Ed. Totowa, NJ, Human Press, 1998, p. 267–279 · DOI
  17. Feyzi E, Saldeen T, Larsson E, Lindahl U, Salmivirta M: Age-dependent modulation of heparan sulfate structure and function. J Biol Chem 273:13395–13398, 1998 · DOI
  18. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 43:527–550, 2000 · DOI · Paper page
  19. Schoonjans K, Martin G, Staels B, Auwerx J: Peroxisome proliferator-activated receptors: orphans with ligands and functions. Curr Opin Lipidol 8:159–166, 1997 · DOI
  20. Zeng B, Mortimer B, Martins IJ, Seydel U, Redgrave TG: Chylomicron remnant uptake is regulated by the expression and function of heparan sulfate proteoglycan in hepatocytes. J Lipid Res 39:845–860, 1998 · DOI · Paper page
  21. Hennig B, Shasby DM, Fulton AB, Spector AA: Exposure to free fatty acid increases the transfer of albumin across cultured endothelial monolayers. Arteriosclerosis 4:489–497, 1984 · DOI
  22. Hennig B, Shasby DM, Spector AA: Exposure to fatty acid increases human low density lipoprotein transfer across cultured endothelial monolayers. Circ Res 57:776–780, 1985 · DOI
  23. Hennig B, Watkins BA: Linoleic acid and linolenic acid: effect on permeability properties of cultured endothelial cell monolayers. Am J Clin Nutr 49:301–305, 1989 · DOI
  24. Ramasamy S, Boissonneault GA, Decker EA, Hennig B: Linoleic acid-induced endothelial cell injury: role of membrane-bound enzyme activities and lipid oxidation. J Biochem Toxicol 6:29–35, 1991 · DOI
  25. Spector AA: Structure and lipid binding properties of serum albumin. Methods Enzymol 128:320–339, 1986 · DOI
  26. Hawkins M, Barzilai N, Hu M, Chen W, Rossetti L: Role of the glucosamine pathway in fat-induced insulin resistance. J Clin Invest 99:2173–2182, 1997 · DOI
  27. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes 47:859–866, 1998 · DOI
  28. Lu G, Morinelli TA, Meier KE, Rozenzweig SA, Egan BM: Oleic acid-induced mitogenic signaling in vascular smooth muscle cells: a role for protein kinase C. Circ Res 79:611–618, 1996 · DOI
  29. Willnow TE: Mechanisms of hepatic chylomicron remnant clearance. Diabet Med 14 (Suppl. 3):S75–S80, 1997 · DOI
  30. Ebara T, Conde K, Kako Y, Liu Y, Xu Y, Ramakrishnan R, Goldberg I, Shachter N: Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. J Clin Invest 105:1807–1818, 2000 · DOI · Paper page

Cited by

Sorted by citations

See all 44

Metadata

Authors
Olsson, U., Egnell, A.-C., Lee, M. R., Lundén, G. O., Lorentzon, M., Salmivirta, M., Bondjers, G., & Camejo, G.
Venue
Diabetes
Publisher
American Diabetes Association
Published
2001-09-01
Volume
50
Issue
9
Pages
2126-2132
ISSN
  • 0012-1797
  • 1939-327X
DOI
10.2337/diabetes.50.9.2126
Cited by
44
References
1
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review